BiotechTube
ReST Therapeutics

ReST Therapeutics

Paris, France· Est.
rest-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

ReST Therapeutics is a Paris-based biotech advancing novel small molecules targeting NMDA receptor subunits for neuropsychiatric conditions. The company's lead program, RST-101, targets early treatment of PTSD, while a second candidate, FENM, has entered clinical development. ReST leverages a precision neuropsychiatry platform, validated preclinical models, and a leadership team with deep drug development expertise, supported by high-profile scientific advisors like Professor John Krystal of Yale University.

NeuropsychiatryPost-Traumatic Stress Disorder (PTSD)Alzheimer's Disease

Technology Platform

Small molecule platform targeting specific subunits of the NMDA receptor for superior efficacy and tolerability in neuropsychiatric disorders.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The large, underserved patient populations in PTSD (300M globally) and Alzheimer's disease represent a significant market opportunity.
The company's precision approach targeting NMDA receptor subunits could yield best-in-class therapies with improved tolerability over non-selective agents.
High-profile scientific validation, such as from SAB member Prof.
John Krystal, enhances credibility and partnership potential.

Risk Factors

High risk of clinical failure associated with novel NMDA-targeting mechanisms in challenging neuropsychiatry indications.
Significant financial risk as a pre-revenue company requiring substantial capital to fund clinical trials.
Intense competition from other biopharma companies developing next-generation psychiatric therapeutics, including NMDA modulators and psychedelics.

Competitive Landscape

ReST operates in the competitive NMDA modulator space, competing with companies developing ketamine derivatives (e.g., Johnson & Johnson's Spravato), other NMDA antagonists, and novel psychedelic-based therapies for PTSD and depression. In Alzheimer's, it faces competition from large pharma and biotech firms focused on amyloid, tau, and other mechanisms. Differentiation hinges on its claimed subunit specificity and precision neuropsychiatry approach.

More companies in Small Molecule Drugs →More companies in France →